2 Dec 2020
*A corporate client of Hybridan LLP
Dish of the day
Conduit Holdings is a newly established reinsurance underwriting business focusing on producing strong risk adjusted returns from a diversified and focused business plan. The business has been formed to capitalise on what the Company’s founders, Neil Eckert and Trevor Carvey believe to be an exceptional market opportunity. Raising $1.1bn (£826m) at 500p. Pricing announced today with unconditional dealings on the Official List (standard segment) to commence on 7 December.
Off the menu
Cathay International Holdings has left the Official List (standard segment).
What’s cooking in the IPO kitchen?
Intuitive Investments Group, a closed-end investment company focussed on the life sciences sector, announces its intention to seek admission the AIM market of the London Stock Exchange plc, and a conditional placing , at a price of 20 pence per share, to raise gross proceeds of £7.5 million . · The net proceeds of the Placing will be used by the Company:- to invest in fast growing and / or high potential life sciences businesses, based predominantly in the UK, wider Europe and the US, chosen from an identified pipeline of investment opportunities – investments will be focused on diagnostics and healthcare, medical devices, tools and technologies and bio-therapeutics and pharmaceuticals · The market capitalisation of the Company is expected to be circa £7.8 million on Admission. Due 14 Dec.
Schroder BSC Social Impact Trust plc targeting a £100m raise. The Company’s investment objective is to be the first London listed investment company to deliver measurable positive social impact as well as long term capital growth and income, through investing in a diversified portfolio of private market impact funds, co-investments alongside impact investors and direct investments in order to gain exposure to private market Social Impact Investments. Due 22 Dec. Official List (premium)
Abingdon Health to list on AIM. Abingdon Health is a lateral flow diagnostics company providing contract service solutions to a global client base in the healthcare sector and other industries . The Company has developed and is manufacturing the AbC-19TM Rapid Test, an antibody test for Covid-19 indicating whether a person is generating IgG antibodies to the spike protein of the SARS-CoV-2 virus. The Company is also working with three customers to transfer their Covid-19 antigen tests to manufacture, and is manufacturing a component of a rapid PCR (polymerase chain reaction) test. Offer TBC. Due early Dec.
Auctus Growth Plc (LON:AUCT) – Reverse acquisition of HeiQ Materials AG. £20m placing for the enlarged group plus further secondary placing of £40m for selling shareholders. HeiQ creates technologies that add functionality, comfort, hygiene and sustainability to existing apparel, home textiles, technical textiles, medical textiles and devices and functional consumer products. It is anticipated that the funds raised will be used to strengthen the Enlarged Group’s regulatory portfolio, enhance its direct to consumer marketing and build brand equity, expand its geographical footprint, expand its sales channels, upscale the product HeiQ GrapheneX and build a medical business unit in light of the robust growth that HeiQ Viroblock has experienced due to the COVID-19 global pandemic. Anticipated mkt cap £141 million. Due 7 Dec. Main Mkt (Standard)
Helium One Global to join AIM. The Company, through its Tanzanian subsidiaries, holds a 100% interest in 18 licences (the Priority Licences) covering an area of 4,512km2 with an Unrisked Prospective Helium Resource (2U) of 138Bcf (SRK 2019). The Company has spent US$8.25m on exploration, assessment and related activity to date and is now drill ready. Capital to be raised on Admission: £6million. Anticipated market capitalisation on Admission £14.1 million (at the issue price of 2.84p). Due 4 Dec
Downing Renewables & Infrastructure Trust intends to raise up to £200 million to target the acquisition of a diversified portfolio of renewable energy and other infrastructure assets and list on the Official List of the Financial Conduct Authority and Main Market of the London Stock Exchange . Due by mid December
Ecofin U.S. Renewables Infrastructure Trust. Initial public offering of up to us$250 million to invest in a diversified portfolio of mixed US renewable energy assets with an attractive long-term income stream. Main market premium. Due 14 Dec
VH Global Sustainable Energy Opportunities plc, a closed-ended investment company focused on making sustainable energy infrastructure investments, today announces intends to launch an initial public offering of shares on the Official List (Premium) of the Financial Conduct Authority and Main Market of the London Stock Exchange. Due by Early Feb 2021
Tirupati Graphite, the fully-integrated, cash generative, specialist graphite and graphene producer with operations in Madagascar and India, announced its potential intention to undertake an initial public offering on the LSE (standard listing). Raising £6m. Mkt cap c.£33.6m. Due 11 December
Bytes Technology Group one of the UK’s leading software, security and cloud services specialists, announces that the Company intends to publish a Registration Document and is considering proceeding with an initial public offering (Main Mkt Prem). FY20 gross profit of £79.2m (+24.5% against FY19) and adjusted operating profit of £31.7m (+53.9% against FY19). Highly cash generative with FY20 cash conversion of 125.9% (FY19 cash conversion 139.7%). Bytes due on or around 17 December 2020.
Mailbox REIT PLC , a newly formed single asset company which owns the Mailbox , a large prime office-led mixed use property in Birmingham which has been independently valued at £179m, announced its intention to raise up to £62.5m. MailBox REIT will apply for the Ordinary Shares be admitted to trading on the IPSX Prime segment of International Property Securities Exchange (IPSX ). Due 14 December.
Umuthi Healthcare Solutions Plc, the technology led healthcare business focused on the distribution of pharmaceuticals and the provision of medical facilities in remote areas, seeking admission to the Standard Listing segment of the Official List. Timing tbc
Kibo Energy PLC, the multi-asset Africa focused energy Company, is seeking admission for its 100% owned UK subsidiary Sloane Developments Ltd , which will be renamed Mast Energy Developments PLC (MED), to the Standard List of the London Stock Exchange plc. The MED business strategy is to acquire and develop a portfolio of flexible small-scale power generation assets, exploiting a growth niche market in the UK for Reserve Power generation to balance out the national grid at critical times. Targeted for Q4 2020.
Ethernity Networks 27p £11.26m (LON:ENET)
The supplier of data processing offload solutions on programmable FPGA (field programmable gate array) hardware for accelerating telco/cloud networks, provided a market update:
· Revenue momentum with H2 2020 expected to be in line with market expectations (FY20: c. $2.0 million), representing growth of ~400% over H1 2020 and similarly H2 2019.
· Increasing visibility over 2021 forecast revenue with approximately 60% forecast revenue currently anticipated from existing ENET licensing contracts, subject to customer confirmations of order volumes.
· Testing of ACE-NIC100 fully integrated within 5G deployment – selected over two major SmartNIC competitors’ offerings. Larger scale commercial field trial now expected in 2021.
Empresaria Group 43p £20.9m (LON:EMR)
The global specialist staffing group, provides the market with an update on trading for the current financial year ending 31 December 2020.
The Group has continued to demonstrate the financial benefits of its diversity by both geography and sector through the third quarter and the first part of the fourth quarter. Having delivered profits in the first quarter and in the second quarter under extremely challenging circumstances, the Group has continued to progress in the second half delivering profits in each month to date (adjusted profit before tax). Evidence of recovery is being seen across many parts of the Group but this remains slow in some cases and local conditions can be volatile as each location reacts to the ongoing impact from coronavirus.
“We anticipate that the Group’s full year net fee income will be in the range of £52m to £55m and adjusted profit before tax is expected to be in the range of £4.4m to £4.9m. At 30 October adjusted net debt was £11.4m, the increase from 30 June primarily reflecting the repayment of certain tax liabilities which were deferred in the second quarter of 2020 and the impact of increased working capital requirements as net fee income has improved. We would expect net debt to continue to return towards pre-COVID levels as net fee income recovers. Headroom remains strong at £17.6m excluding invoice financing facilities (30 June 2020 £18.1m).”
The data solutions provider, announces two new significant contract upgrades in the financial services sector for the Group’s Celebrus customer data platform (CDP). These contract upgrades will add a further c.£3.5 million to revenue in the current financial year and bring the total added to second half revenue from recent contract successes, as announced on 5 November 2020, to c.£9 million.
Boku 128p £368m (LON:BOKU)
The mobile payment and mobile identity company provided an unaudited trading update for the year ending 31 December 2020. As a result of continued strong trading in the Company’s Payments businesses, together with a benefit from COVID-19 related cost savings, the Boku board now expects Group EBITDA for the year ending 31 December 2020 to be at least $13.5 million, at least $1 million higher than the current consensus market forecast.
Portfolio company Solar Foods Oy, focussed on developing its novel protein Solein, has received EUR4.3 million of new funding to support its EUR8.6 million development project for the commercialisation of Solein, its novel protein made from air. Agronomics has a 5.35% equity interest (on a fully diluted basis) in Solar Foods following a EUR3.0 million investment in September 2020.
Surgical Innovations 1.45p £13.5m (LON:SUN)
The designer, manufacturer and distributor of innovative medical technology for minimally invasive surgery, announces that its wholly owned subsidiary, Elemental Healthcare Ltd, has successfully launched the new biological matrix range for Breast Reconstruction, manufactured by Meccellis.
Cellis Breast is a comprehensive range of biological matrices for Breast Reconstruction which received their CE mark in April 2020. Trials were delayed as a consequence of the NHS response to Covid-19; however with the resumption in some hospitals of breast reconstruction, evaluations have been successfully carried out which has meant the Company has met its Q4 target for UK market launch of the product.
Elemental’s Project Management team worked with key surgeons at selected hospitals to understand optimal practice and techniques. This product knowledge has been shared with the wider sales team and Elemental now has a number of accounts at the later stages of evaluation and purchasing.
Jangada Mines 4.65p £11.26m (LON:JAN)
The natural resources company notes the recent announcement released on 1 December 2020 by TSX-V listed ValOre Metals Corp., in which Jangada holds a 17.68 per cent interest.
ValOre Drills 76.74 metres of 1.25 g/t 2PGE+Au, incl. 15.00 m at 4.19 g/t 2PGE+Au, 0.63% Ni and 0.25% Cu at Pedra Branca.
“The 2020 drilling at Trapia 1 was a great success, delivering a very strong finish with the assay results received from hole DD20TU20,” stated ValOre’s Chairman and CEO, Jim Paterson. “Importantly, for future recalculations of mineral resource estimates, the drilling results suggest that the ore body thickens at depth and also that mineralization remains open in all directions.”
The personalised healthcare company, announces the launch of its DNA testing service, following the recent acquisition of The Genome Store. The testing service will be launched today under the new MyHealthChecked ™ brand and the first test swab kit available will be a fast and reliable direct to consumer COVID-19 lab-based PCR test available to the UK public via a new ecommerce website.
The MyHealthChecked™ COVID-19 testing service will use the Clarigene® SARS-CoV-2 test supplied by Yourgene Health plc (AIM: YGEN) and the PrimeStore® MTM sample collection device supplied by EKF Diagnostic Holdings plc (AIM: EKF). The MyHealthChecked™ testing service allows samples to be quickly and conveniently taken at home using simple nasal collection swabs which are then sent via free postage for processing using established laboratory-based DNA and RNA detection methods.
The Company also confirms that it will change its name to MyHealthChecked ™ Plc. Trading in the Company’s shares on the AIM market of the London Stock Exchange under the new name is expected to take effect in due course and the Company’s stock exchange ticker is also expected to change from CPT to MHC.
Alba Mineral Resources 0.445p £27.6m (LON:ALBA)
The first phase of the Company’s underground drilling programme at the Clogau-St David’s Gold Mine , which was completed in October 2020, has intersected what Alba believes to be the westerly extension to the Clogau Main Lode, representing a potential 550-metre extension to the Main Lode. The Main Lode is the source of most of the historic gold production at the Mine.
· Drillhole L002 returning significant gold assays of 1.16 metres at 0.653 grammes/tonne (“g/t”), including 0.25 metres at 1.79 g/t.
· Drillholes L002 and L003 have intersected what Alba believes to be the westerly extension of the Clogau Main Lode, representing a 550-metre extension to the Main Lode, the source of most historic production at the Clogau-St David’s Gold Mine.
· Infill surface and underground drilling is now planned to confirm the continuity of the Main Lode extension.
The vendor of cloud-based cybersecurity software announced a significant contract win for its Privileged Access Management (PAM) technology with a major UK provider of telephone, broadband and mobile services.
The new customer has purchased an initial 36 month term enterprise license for the Osirium PAM platform including the Privileged Access Management, Privileged Task Management and Privileged Session Management modules. Consultancy and training from Osirium Professional Services are included in the contract.
The Osirium PAM platform has been selected in a competitive bid against a range of other PAM vendors as part of a sales initiative led jointly by Osirium and Infradata, an independent provider of state-of-the-art cyber security and cloud networking solutions and services and an approved Osirium reseller partner.
0203 764 2344
Status of this Note and Disclaimer
This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.
Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document is sent to you as market commentary only. As market commentary this document does not constitute any of (i) investment research and financial analysis or other forms of general recommendation relating to transactions in financial instruments for the purposes of section B of annex I to Directive 2014/65/EU (“MIFID II Directive”); or (ii) investment research as defined in article 36(1) of Commission Delegated Regulation 2017/565/EU made pursuant to the MIFID II Directive; or (iii) non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook).
This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as “relevant persons”). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.